Italian Biotech Startup NanoPhoria Secures €83.5M for Heart Failure Therapy
Italian biotech startup NanoPhoria Bioscience has secured €83.5 million in a Series A round, led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital. Panakès Partners and one undisclosed investor also participated. The funding will fuel the development of their innovative therapy for heart failure with reduced ejection fraction (HFrEF), a condition affecting over 60 million people worldwide.
NanoPhoria's lead therapy, NP-MP1, targets L-type calcium channels in heart muscle cells, aiming to enhance contractility and ejection fraction. Current treatments focus on symptom relief and slowing disease progression, but they cannot directly restore cardiac function. The company's lung-to-heart nano-in-micro delivery system has shown promising results in preclinical models.
Founded in 2022, NanoPhoria is a spin-off of Italy's National Research Council (CNR) and joins a growing wave of European startups combining advanced materials science with precision cardiology. Other notable startups in this field include inHEART, Idoven, Certis Therapeutics, Verdify, and InCarda Therapeutics.
The substantial funding will accelerate NanoPhoria's development of NP-MP1, potentially revolutionising cardiovascular medicine. With over 60 million people affected by HFrEF globally, this therapy could significantly improve patients' lives. The successful funding round underscores investors' confidence in NanoPhoria's innovative approach.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
